Ordinary Index Rebalancing in the Solactive China Biotech Index | January 2021

In the ordinary rebalance the following composition will be implemented effective open 11.01.2021:

3SBIO INC
ANHUI ANKE BIOTECHNOLOGY G-A
BEIGENE LTD-ADR
BEIJING TIANTAN BIOLOGICAL-A
BERRY GENOMICS CO LTD-A
BETTA PHARMACEUTICALS CO L-A
BGI GENOMICS CO LTD-A
CANSINO BIOLOGICS INC
CHINA BIOLOGIC PRODUCTS HOLD
CHINA MEDICAL SYSTEM HOLDINGS LTD
CHINA NATIONAL MEDICINES-A
DA AN GENE CO LTD SUN YAT-A
GENSCRIPT BIOTECH CORP
HANSOH PHARMACEUTICAL GROUP CO
HUALAN BIOLOGICAL ENGINEER-A
HUTCHISON CHINA MEDITECH-ADR
INNOVENT BIOLOGICS INC
JIANGSU HENGRUI MEDICINE CO LTD CLASS A
LIVZON PHARMACEUTICAL GROU-A
NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
PHARMABLOCK SCIENCES NANJI-A
SHANGHAI JUNSHI BIOSCIENCES CO LTD
SHANGHAI RAAS BLOOD PRODUC-A
SHENZHEN KANGTAI BIOLOGICA-A
SINO BIOPHARMACEUTICAL LTD ORD
WALVAX BIOTECHNOLOGY CO-A
WUXI APPTEC CO LTD-A
WUXI BIOLOGICS CAYMAN INC
ZAI LAB LTD
ZHEJIANG WOLWO BIO-PHARMAC-A